 |
|
| Dow | Nasdaq | About Us | Disclaimer |  |
RSS Feed |  |
Follow us on Twitter |
|
Featured Advisors |
Monday March 19, 2012
Celgene: Poised for a breakout?
by Leo Fasciocco, editor Ticker Tape Digest  Celgene (CELG) produces drugs to treat cancer and immune-inflammatory related diseases. Annual revenues are $4.8 billion. Its primary commercial-stage products include Revlimid, Vidaza, Thalomid and Abraxande. It also has licensing deals with Novartis. CELG has also been active in making acquisitions. CELG's long-term chart shows the stock soaring from 5 back in 2003 to a peak of 77 in 2008.The stock has now regrouped and is pushing once again toward its breakpoint. The accumulation - distribution line is in an up trend and is showing strong buying. That bodes well for a breakout to a new all-time high. For 2012, analysts forecast a 29% jump in CELG's earnings to $4.41 a share from $3.43 a year ago. The stock sells with a price-earnings ratio of 17. We see that as low making the stock a good value-growth play. Net for the upcoming first quarter should soar 45% to $1.03 a share from 71 cents a year ago. The highest estimate on the Street is at $1.12 a share. We see chances for an upside surprise. In the prior quarter, CELG topped the consensus estimate by 2 cents a share and the quarter before that by 11 cents a share. Looking out to 2013, Wall Street projects an 18% gain in net to $5.18 a share from the anticipated $4.41 this year. We suggest accumulation of a partial stake in CELG with further buying to be done on a breakout over 75.10. We are targeting CELG for a move to 90 after a breakout. A protective stop can be placed near 71. Institutional sponsorship is excellent. A key fund buyer recently was 4-star rated Fidelity Contrafund which purchased 528,200 shares. Also, 4-star rated Harbor Capital Appreciation Fund was a recent buyer of 162,946 shares. Insider activity is bullish. Insiders have been selective buyers of the stock in recent months. Their latest buys have come around $61. Currently, 27 analysts follow the stock, 19 have a buy, down from 22 three months ago. Learn more about this financial newsletter at Leo Fasciocco's Ticker Tape Digest. Related articles: 
|
News Flash
|
|